Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > The risk of myocarditis is increased but remains low after the first booster dose with an mRNA vaccine, and this risk decreases with increasing time between doses

https://ansm.sante.fr/actualites/le-risque-de-myocardite-est-augmente-mais-reste-faible-apres-la-premiere-dose-de-rappel-par-un-vaccin-a-arnm-et-ce-risque-diminue-avec-lallongement-du-delai-entre-les-doses

Marie Berger 1 August 2022 All news
  • ← EU : list of medicinal products under additional monitoring
  • Covid-19 Vaccine Surveillance Update – Period 17-Jun-2022 to 21-Jul-2022 →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • European contact points for clinical trials
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023
  • Clinical Trials Regulation (EU) No 536/2014 in practice
Copyright © 2018 - Pharmya - Legal terms - Quality Policy